| |
|
 |
| DermiPsor Reaches Phase III in Record Time
With Psoriasis Drug | | “We expect to launch DPS-101 in the $1 billion topical psoriasis market within 2 and a half years,” says CEO Ze’ev Even-Chen. | | read full article... |
|
|
 |
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
 |
 | ILSI-Biomed on May 27-29 in Tel Aviv
More than 6,000 Visitors Expected | | Mayor Don Plusquellic is leading a delegation from Akron, Ohio that will invite Israeli companies to participate in a $1.6 Billion biotech program. | | read full article... |
|
|
|
|
|
| |
|
|
|
|
|
| |
|
 |
| PhagoLum Develops Sepsis Test
Clinical Trials Planned for 2009 | | "We are taking a mathematical model for building clinical profiles to detect sepsis early," says Avi Reinhartz, CEO of Phagolum. | | read full article... |
|
|
|
|
|
| |
|
 |
| Marc Weinzweig, Managing Director, Biotec
Clinical Trials Supply Company Sponsors Cycle Ride FundRaiser | | Cyclists will follow a route starting in Northern Israel and finishing in Tel Aviv on May 27 the first day of BioMed Israel 2008.
| | read full article... |
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
|
|
| |
|
top of the page
|
|
